Literature DB >> 24366942

Plasma fetuin-A levels are reduced in patients with hypothyroidism.

Okan Bakiner1, Emre Bozkirli, Derun Ertugrul, Nurzen Sezgin, Eda Ertorer.   

Abstract

OBJECTIVE: To determine plasma fetuin-A levels in hypothyroid patients before and after treatment with l-thyroxine (T4) and to determine the relation between plasma fetuin-A levels with cardiovascular risk factors.
DESIGN: A prospective, controlled, single-blind study.
METHODS: Forty-four treatment-naive female patients diagnosed with hypothyroidism and 39 age- and sex-matched control subjects were enrolled. Anthropometric measurements, blood pressure, plasma TSH, fetuin-A, free T4, LDL-cholesterol, triglyceride, C-reactive protein, fibrinogen levels, and brachial artery flow-mediated dilatation were measured. All measurements were repeated after 3 months in the control group and 3 months after the attainment of euthyroidism with l-T4 replacement in the hypothyroid group. Baseline data were compared between the two groups. Posttreatment plasma fetuin-A levels of hypothyroid patients were compared with baseline levels of both groups. The relationship between plasma fetuin-A, TSH levels, and other cardiovascular risk factors was evaluated.
RESULTS: Plasma fetuin-A levels were ∼20% lower in hypothyroid female patients compared with the controls (P=0.0001). Fetuin-A levels increased by ∼20% in hypothyroid patients after achievement of euthyroidism (P=0.0001) and were no longer different compared with controls (P=0.38). There was a negative correlation between plasma TSH and fetuin-A levels (r=-0.79; P=0.001). There was no significant correlation between plasma fetuin-A levels and cardiovascular risk factors within or between groups. The fetuin-A levels were normalized with thyroid hormone treatment.
CONCLUSION: Plasma fetuin-A levels are reduced in female patients with hypothyroidism, which are restored to normal during restoration of euthyroidism. There was no relation with cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24366942     DOI: 10.1530/EJE-13-0831

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

1.  Serum levels of fetuin-A are negatively associated with log transformation levels of thyroid-stimulating hormone in patients with hyperthyroidism or euthyroidism: An observational study at a medical center in Taiwan.

Authors:  Fen-Yu Tseng; Yen-Ting Chen; Yu-Chiao Chi; Pei-Lung Chen; Wei-Shiung Yang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

2.  Elevated serum neuregulin 4 levels in patients with hyperthyroidism.

Authors:  Min Li; Ying Chen; Jingjing Jiang; Yan Lu; Zhiyi Song; Shengjie Zhang; Chao Sun; Hao Ying; Xiaofang Fan; Yuping Song; Jialin Yang; Lin Zhao
Journal:  Endocr Connect       Date:  2019-06-01       Impact factor: 3.335

Review 3.  Interplay between Fatty Acid Binding Protein 4, Fetuin-A, Retinol Binding Protein 4 and Thyroid Function in Metabolic Dysregulation.

Authors:  Daniela Dadej; Ewelina Szczepanek-Parulska; Marek Ruchała
Journal:  Metabolites       Date:  2022-03-29

Review 4.  The role of thyroid hormone in metabolism and metabolic syndrome.

Authors:  Patrícia de Fátima Dos Santos Teixeira; Patrícia Borges Dos Santos; Carmen Cabanelas Pazos-Moura
Journal:  Ther Adv Endocrinol Metab       Date:  2020-05-13       Impact factor: 3.565

5.  Elevated Serum Growth Differentiation Factor 15 Levels in Hyperthyroid Patients.

Authors:  Jiejie Zhao; Min Li; Ying Chen; Shengjie Zhang; Hao Ying; Zhiyi Song; Yan Lu; Xiaoying Li; Xuelian Xiong; Jingjing Jiang
Journal:  Front Endocrinol (Lausanne)       Date:  2019-01-09       Impact factor: 5.555

6.  Elevated Serum Tsukushi Levels in Patients With Hyperthyroidism.

Authors:  Deying Liu; Peizhen Zhang; Xueyun Wei; Yajuan Deng; Wenhui Liu; Dan Guo; Jianfang Liu; Bingyan Xu; Chensihan Huang; Junlin Huang; Jiayang Lin; Shiqun Liu; Yaoming Xue; Huijie Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-29       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.